Up in smoke: the SRI case for marijuana (Citywire Selector)


Marijuana’s hip image is changing into something altogether more pedestrian thanks to its rising profile in medicine. Extracts of cannabis have been recommended for anorexia, pain relief and epilepsy. As the substance swaps the streets for the pharmacy shelves, some investors spy an opportunity.

In 2016 the medical marijuana market posted revenues of $6.3 billion, up from 30% the previous year. In 2017, two marijuana-focused ETFs were launched comprising stocks such as British firm GW Pharmaceuticals and Canada-based medical cannabis group Canopy Growth Corporation.

- Promotion -



Partner message

COVID-19 has led to a new appreciation of the importance of healthcare in ensuring all members of society thrive. So where should investors be looking to find resilience in an industry facing enormous change?

Continue to read

NordSIP Insights

Most read this week

Sony Kapoor to Advise Worthwhile Capital Partners

Stockholm (NordSIP) - Worthwhile Capital Partners, a Nordic sustainable investment placement agent, announced the expansion of its sales force and expertise to extend its business...